Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.